Publications

At Braeburn, we are leveraging our focus on opioid use disorder to work with the healthcare community and advance research, education and support to help end the opioid overdose epidemic.

List of Publications

© 2019 Braeburn Inc. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. https://doi.org/10.1111/add.14636

JAMA Intern Med. 2018;178(6):764–773. doi:10.1001/jamainternmed.2018.1052. Copyright © (2018) American Medical Association. All rights reserved.

JAMA Psychiatry. 2017;74(9):894–902. doi:10.1001/jamapsychiatry.2017.1874. Copyright © (2017) American Medical Association. All rights reserved.

Journal of Substance Abuse Treatment. Volume 78, 22 – 29. Copyright © 2017 Elsevier Inc. All rights reserved.

Advances in Therapy (2017) 34: 560. https://doi.org/10.1007/s12325-016-0472-9. Copyright © Springer Healthcare 2017.

Poster Presentations

2019

AMCP (Academy of Managed Care Pharmacy) March 25-28, San Diego, California

Quality of life in adult outpatients with opioid use disorder treated with long-acting subcutaneous injection buprenorphine depot: Results from an open-label multicenter clinical trial

Carter J, Frost M, Budilovsky-Kelley N

ASAM (American Society of Addiction Medicine) April 4-7, Orlando, Florida

Correlates Of Fentanyl Use In A Controlled Trial Of Injectable Weekly/Monthly Buprenorphine

Nunes E, Comer S, Lofwall M, Walsh S, Peterson S, Budilovskey-Kelley N, Tiberg F, Kim S

ISPOR May 18-22, New Orleans, Louisiana

Clinical and Economic Impact of Relapse in Patients with Opioid Use Disorder in the US

Budilovsky-Kelley N, Kim S, Polson M, Williams T

ASCP (American Society of Clinical Psychopharmacology) May 28-31, Scottsdale, Arizona

Patient Satisfaction With Injectable Weekly and Monthly Buprenorphine and Buprenorphine Treatment Experience

Bailey G, Frost M, Kim S, Budilovsky-Kelley N, Tiberg F

2018
ASAM (American Society of Addiction Medicine): April 12-13, San Diego, California
Transitioning patients from sublingual to injectable weekly and monthly buprenorphine
Frost M, Bailey G, Kim S, Budilovsky-Kelley N
AMCP (Academy of Managed Care Pharmacy): April 23-26, Boston, Massachusetts
Economic impact of flexible-dose depot-injectable buprenorphine versus sublingual buprenorphine/naloxone to treat opioid addiction in persons primarily abusing heroin
Frost M, Carter J, Kim S, Budilovsky-Kelley N
CPDD (The College on Problems of Drug Dependence): June 11-12, San Diego, California
Phase 3 trial comparing depot buprenorphine (CAM2038) to sublingual buprenorphine/naloxone for OUD treatment: Subanalysis among persons with heroin as the primary opioid of abuse
Frost M, Lofwall M, Bailey, G, Walsh S, Beacker M, Budilovsky-Kelley N, Tiberg F
A real-world efficacy and safety comparison of CAM2038 vs SL BPN/NX for the treatment of patients with OUD who inject opioids

Bailey F, Frost M, Lofwall M, Walsh S, Budilovsky-Kelley N, Tiberg F

ISAM (International Society of Addiction Medicine) November 3-6, Busan, Republic of Korea

Converting patients from daily sublingual buprenorphine/naloxone to weekly and monthly buprenorphine injections

Kim S, Frost M, Lintzeris N, Bailey G, Dunlop A, Budilovsky-Kelley N, Tiberg F

ISPOR Europe (The Professional Society for Health Economics and Outcomes Research) November 10-14, Barcelona, Spain

Quality of life according to temporal illicit opioid use and responder rate in adults receiving buprenorphine depot injections (CAM2038) to treat opioid use disorder in a 48-week open label study

Rasmussen MA, Frost M, Jensen R, Budilovsky N, Kim S, Tiberg F

Quality of life according to responder rate in opioid dependent adults receiving treatment with buprenorphine depot injections (CAM2038) versus sublingual buprenorphine/naloxone

Jensen R, Rasmussen MA, Frost M, Budilovsky N, Kim S, Tiberg F

AAAP (American Academy of Addiction Psychiatry): December 6-9, Bonita Springs, Florida
Patient satisfaction and experience with weekly/monthly sustained-release injectable buprenorphine
Bailey G, Frost M, Kim S, Tiberg F, Budilovsky-Kelley N

Impacts of relapse status and responder rate on quality of life in adults treated with CAM2038 for opioid use disorder

Frost M, Tiberg F, Carter J, Rasmussen M, Kim S, Rasmus J, Budilovsky-Kelley N

2017
AMCP (Academy of Managed Care Pharmacy): March 27-30, Denver, Colorado
Employing bayesian-calibrated microsimulation to assess the cost-effectiveness of long acting injectable buprenorphine versus sublingual buprenorphine to treat opioid use disorder
Carter J, Dammerman R, Frost M, Tiberg F
AMCP Nexus (Academy of Managed Care Pharmacy): October 16-19, Dallas, Texas
Determining the economic impact of medication non-adherence in persons treated with depot-injectable or sublingual buprenorphine for opioid use disorder
Carter J, Frost M, Sanjurjo V
ATHS (Addictions Toxicomanies Hépatites SIDA): October 17-20, Biarritz, France
Long-term safety, tolerability and effectiveness of weekly and monthly buprenorphine depots (CAM2038) for opioid use disorder: European and Australian experience
Dunlop A, Frost M, Lintzeris N, Nunes E, Bailey G, Billeskov Jansen J, Chemnitz Frey L, Weber B, Strang J, Kim S, Tiberg F
Lisbon Addictions October 24-26, Lisbon, Portugal
Long-term safety, tolerability and effectiveness of weekly and monthly buprenorphine depots (CAM2038) for opioid use disorder
Dunlop A, Frost M, Lintzeris N, Nunes E, Bailey G, Billeskov Jansen J, Chemnitz Frey L, Weber B, Strang J, Kim S, Tiberg F
SSA (Society for the Study of Addiction): November 9-10, Newcastle, UK
Long-term safety, tolerability and effectiveness of weekly and monthly buprenorphine depots (CAM2038) for treatment of opioid dependence: A European, Australian and U.S. Phase 3 study
Strang J, Dunlop A, Frost M, Lintzeris N, Nunes E, Bailey G, Billeskov Jansen J, Chemnitz Frey L, Weber B, Kim S, Tiberg F

Define the future at Braeburn...together.

Join Our Team